Home › Clinical Trials › Cancer Clinical Trial › Pancreas › MM-398-07-02-03: A randomized, open-label phase 2 study of irinotecan liposomal injection (lip-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma